Supplementary Figure S1 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Supplemental Figure SF1. Time-dependent Kaplan-Meier analysis based on Distant Recurrence comparing extended letrozole vs placebo in subsets of patients treated with initial adjuvant endocrine therapy with either A, AI only or B, a sequence of tamoxifen followed by AI in the overall Breast Cancer Index (BCI) NSABP B-42 translational cohort.